All In Biotech

Drug Trial Radar · NCT07679282

A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults

Comparative Effectiveness of Positive Airway Pressure Therapy, Dental Device, and Atomoxetine-Oxybutynin for Sleep Apnea: the ADAPT-OSA Study

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,400

Planned (sponsor's estimate)

Start

Sep 4, 2026

Primary completion

Mar 1, 2030

Study completion May 1, 2032

Sponsor

Lead sponsor
Sairam ParthasarathyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Patient-Centered Outcomes Research Institute; University of Arizona; University of Maryland; University of Miami; Stanford University
First posted
Jul 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers want to identify which treatments for obstructive sleep apnea (OSA) work best and are easiest for patients to use consistently. Eligible participants will be randomly assigned one of three OSA treatments: traditional PAP therapy, a dental device, or a combination of two FDA-approved medications (atomoxetine and oxybutynin) that are currently approved for other conditions. Over the course of one year, participants will attend two in-person visits and take part in four phone check-ins to complete surveys, report any side effects, and discuss how well they are following their assigned treatment.

Conditions

  • Obstructive Sleep Apnea (OSA)

Interventions

  • Positive airway pressure (PAP) therapyDevice

    Positive airway pressure delivered via a nasal or face mask while a patient sleeps to keep the airways open.

  • Sleep dental deviceDevice

    An oral appliance worn during sleep to move the lower jaw forward, which tightens soft tissues and widens the airway to prevent sleep apnea.

  • Atomoxetine-oxybutyninDrug

    The combination of two medications (atomoxetine-oxybutynin) can reduce obstructive sleep apnea by increasing upper airway muscle activity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Health-related quality of lifeTime frame: At 12 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Banner University Medical Center Tucson

    Tucson, Arizona · Recruiting

  • Stanford Medical Center

    Redwood City, California · Recruiting

  • University of Miami Miller School of Medicine

    Miami, Florida · Not yet recruiting

  • University of Maryland Baltimore

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.